# Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

> **NCT02309450** · PHASE2 · WITHDRAWN · sponsor: **ANRS, Emerging Infectious Diseases**

## Conditions studied

- Hepatitis C Virus Genotype 4 Infection

## Interventions

- **DRUG:** .Asunaprevir, Daclatasvir and BMS - 791325

## Key facts

- **NCT ID:** NCT02309450
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2015-11
- **Final completion:** 2016-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** BMS decision
- **Last updated:** 2016-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02309450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02309450, "Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02309450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*